Elizabeth Herman is an executive director on the federal government relations team of JPMorgan Chase & Co.   She joined JPMorgan Chase after serving for six years as legislative counsel to Senator Claire McCaskill.  During her time on Capitol Hill, Elizabeth specialized in tax and financial policy and was the Senator’s lead staffer for issues before the Senate Finance Committee, Permanent Subcommittee on Investigations and the Special Committee on Aging.   Elizabeth is a tax lawyer by trade, previously working for a senior member of the House Ways & Means Committee and as an associate in the derivatives / tax division of Thacher Proffitt & Wood LLP.  She holds a master’s degree in tax from NYU School of Law, a law degree from the University of Wisconsin Law School, and an undergraduate degree from Cornell University.

As a member of the Board of Directors and LumaCyte’s President and Chief Business Officer, Renee leads LumaCyte’s corporate development and investor relations, as well as global sales and marketing.  She brings over 20 years of executive level business development, operations and strategic partnering experience across the biopharmaceutical, software and clinical development service arenas. Renee’s expertise in managing large scale, highly complex strategic partnerships has garnered her many long-term trusted relationships and oversight across significant multi-million dollar partnerships and transactions in the life science space.

Prior to joining LumaCyte, Renee was SVP and head of the global partner business unit for Medidata Solutions where she led strategic efforts for driving deeper and broader global market penetration of Medidata’s clinical cloud platform for clinical trials.  She has also held executive level roles at both Syneos Health (previously inVentiv Health) and Clinipace Worldwide, bringing valuable corporate and executive level leadership and governance experience to her role.

Renee’s experience and earned expertise has touched every aspect of the biopharmaceutical and life sciences industry, providing her a unique perspective into the needs and challenges of the market.  Her collaborative spirit and strong focus on solution management coupled with her philosophy of driving growth through innovation and high trust partnership is proving very valuable in accelerating the adoption of LumaCyte’s transformative, game changing Laser Force Cytology (LFC) ^TMtechnology and global business.  Renee has a Bachelor of Science degree in biology from Marshall University.

Dr. Hart is a highly accomplished leader, innovator and scientist who has developed transformative, cutting edge technologies throughout his career. In 2012, Dr. Hart founded LumaCyte, a revolutionary biopharmaceutical research, instrumentation, and bioanalytics company. LumaCyte offers biopharmaceutical and biomanufacturing companies an advanced label-free approach to single cell analysis and sorting. Dr. Hart led his team over a 12-year period of development at the Naval Research Laboratory (NRL), managing approximately $15M in initial funding, where the core technologies underlying LumaCyte’s products were born. As the original inventors of this novel technology, Dr. Hart and his team have pioneered the scientific advances that have enabled label-free single cell analysis and sorting to be a reality today.

Dr. Hart’s leadership and drive have been cornerstone to LumaCyte’s success and global growth trajectory. His tenacity has been instrumental from corporate inception, accelerating product development and corporate operations, to supporting business development and ongoing R&D.  He also serves as LumaCyte’s Chairman of the Board. Dr. Hart expects that LumaCyte’s innovative Laser Force Cytology technology will transform personalized medicine, as LumaCyte products may be used to advance customized patient treatments, enabling a more efficient and effective approach in accelerating therapies and find cures.

Dr. Hart has authored 60+ peer reviewed journal articles, numerous invited and contributed presentations, as well as 8 patents issued and 12 pending.  Dr. Hart has extensive experience in a diverse range of research areas including spectroscopy, fiber-optics, laser trapping and separation, optical engineering, chromatography, chemical and biochemical separation, multivariate statistical data analysis/calibration, artificial intelligence and machine learning. Dr. Hart received his PhD in Chemistry from Tufts University in 1998.  Dr. Hart resides with his wife, Renee, and their three children, Rowan, Sinclaire and Harrison on a farm in Keswick, Virginia.

Elizabeth McCargo is Vice Consul for the Life Sciences & Healthcare Sector at the British Embassy in Washington DC. Her role is to identify and provide advice and assistance to US Life Sciences & Healthcare companies interested in establishing or expanding operations in the UK (Foreign Direct Investment) and working with UK companies looking to establish a presence in the US (Trade & Overseas Direct Investment).  From DC, she covers the Mid-Atlantic and Southern Regions of the US, engaging with clients in 12 States from Delaware to Florida, eastward to Mississippi, plus Puerto Rico.  She also assists with Ministerial and Government Senior Officials Visits, Trade Missions, etc., with the aim of building relationships and promoting the UK’s strengths in life sciences.

The UK Department for International Trade (DIT) is responsible for bringing together policy, promotion, and financial expertise to break down barriers to trade and investment, helping businesses succeed and delivering a new trade policy framework for the UK as it leaves the EU, promoting British trade and investment across the world and building the global appetite for British goods and services.

Before moving to Washington DC in November 2015, she worked for the Welsh Government’s Economic Development Department for 11 years.

Jean-Charles Soria joined Medimmune Sept 13, 2017 as Senior Vice President of R&D and Head of Oncology iMED. Dr Soria has overall responsibility for the global oncology portfolio at Medimmune with oversight of research, translational sciences and clinical development in oncology.

Previously, he was a Professor of Medicine and Medical Oncology at South-Paris University from 2006-2017, and a tenure-track and full-time cancer specialist at Institut Gustave Roussy. Dr Soria trained as a medical oncologist and obtained the Silver medal from Paris Medical School in 1997. He gained a PhD degree in the fundamental basis of oncogenesis in 2001, and completed his training with a two-year post-doctoral fellowship in the Department of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center, Houston, USA, where he has held an Adjunct Professorship in 2012.

During his career, Dr Soria’s main research interests have been: early clinical development, phase I trials across solid tumors, pharmacodynamic biomarkers, lung cancer and personalized medicine. He was also involved in translational research aspects related to precision medicine and tumor progression notably in lung cancer models (INSERM unit 981). Dr Soria has led multiple precision medicine trials including the MOSCATO trial and the French national effort SAFIR02lung trial. Dr Soria was a member of ESMO Executive Committee from 2008 to 2009, and has served as an ASCO committee member from 2006 to 2012. He was the scientific chairman of the ECCO-ESMO 2011 meeting that was held in Stockholm in 2011, and chair of the EORTC-NCI-AACR meeting in Barcelona in 2014, as well as in Berlin in 2016. He was the President of the TAT meeting in 2013, 2015 and 2017 in Paris. He has contributed to over 560 peer-reviewed publications, including publications as first or last author in the New England Journal of Medicine, the Journal of the National Cancer Institute, and the Journal of Clinical Oncology. He was appointed as Editor in Chief of Annals of Oncology for the period 2014-2017.

Cohava Gelber, PhD, MBA, is an executive with over 25 years of experience in discovery and development of immune therapeutics and diagnostics for cancer, autoimmune disease, allergies and infectious diseases. Dr. Gelber held various executive positions in academia (Duke University) and biopharmaceutical companies (ImmuLogic Pharmaceutical Corporation, Molecular Discoveries and MannKind Corporation).

Dr. Gelber has recently launched Caerus Discovery, LLC (CDL) with support from Biowa/ Kyowa Hakko Kirin.  CDL ‘s mission is to discover and develop new antibody-based therapeutics and diagnostics. Prior to founding CDL, Dr. Gelber served as the Chief Scientific & Technology Officer of ATCC, VP of R&D for MannKind Corp- a public company developing therapeutics for diabetes, cancer and autoimmune diseases and was responsible for non-clinical development and clinical immune safety of drugs from pre IND through phase III clinical trials. Dr. Gelber received her Ph.D. from the Weizmann Institute, her MBA degree from Cornell University and post doctorate training at Stanford University.

Dr. Gelber published numerous scientific manuscripts and textbook chapters and she is the inventor of 16 granted patents and 57 patent applications.

Before becoming CEO, Dr. Cherukuri served in multiple roles at Noble Life Sciences including Chief Operations Officer, Chief Scientific Officer, Vice President of Product Development and Operations, and Director of Scientific Affairs.  In her previous roles at Noble, Dr. Cherukuri was instrumental in optimizing new preclinical animal models and streamlining operations to achieve operational efficiency. In addition, Dr. Cherukuri led the successful consolidation of Noble operations at the Spring Valley Laboratories site. Prior to joining Noble, Dr. Cherukuri held positions at the Cleveland Clinic Foundation, National Cancer Institute and University of Maryland where she led projects focused on understanding the basic biology and mechanistic actions in cancer cells. Dr. Cherukuri has expertise in diverse areas of Biology and has 12+ years of research experience in the areas of oncology and stem cell biology.  Dr. Cherukuri completed her PhD in biology at Cleveland State University.

As a Managing Director of the Office of International Investment and Trade at Maryland Department of Commerce, Ms. Pringle is responsible for the State’s international operations, including foreign direct investment attraction and export promotion. Prior to that, Ms. Pringle served as a Regional Manager for Europe, assisting Maryland companies with developing export markets for their products and services, attracting investment from Europe and managing the Maryland European Office in France.

Ms. Pringle holds a Master’s Degree in Public Administration from University of Baltimore, and a Bachelor’s Degree in International Business, Banking and Accounting, from Estonian Business School and a certificate from the Copenhagen Business School in Denmark. Ms. Pringle is a Vice President of State International Development Organizations (SIDO) and serves on the boards of Eastern Trade Council (ETC), DC/MD District Export Council (DEC), Governor’s Subcabinet on International Affairs, The FDI Frontlines Coalition, and the Center for International Business Education and Research (CIBER) at Smith School of Business at the University of Maryland.

Raghav joined NEA as an associate on the healthcare team in 2018. Prior to joining NEA, Raghav was a member of Lazard’s healthcare M&A group in New York. At Lazard, Raghav worked with clients across the life sciences, medical device, and healthcare services sectors.

Raghav graduated from the Roy and Diana Vagelos Program at the University of Pennsylvania, where he earned a B.A. in Biology from the College of Arts and Sciences and a B.S. in Economics from the Wharton School. During his time at the University of Pennsylvania, Raghav conducted both laboratory research and advisory work related to engineered T cell therapy for oncology.

Charles Andres, Ph.D., RAC, is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. He focuses on patent prosecution, strategic patent counseling, IP due diligence, drug and medical device FDA regulatory counseling, invalidity and non-infringement opinions, life-cycle management, Supreme Court and Federal Circuit amicus briefs, and related business matters.

Charlie has significant experience drafting patent applications, prosecuting patent applications in the U.S. and abroad, and evaluating the claims of issued patents. He has won cases before the Board of Patent Appeals and Interferences by brief and on oral argument. Patents Charlie has obtained have been listed in the Orange Book and asserted against a generic pharmaceutical manufacturer, and he has drafted and filed multiple applications for patent term extension. Companies he has obtained patents for have been sold for a cumulative total of approximately $4 billion.

Charlie has also drafted and prosecuted patents covering three FDA approved drugs. He represented a client at a U.S. Senate HELP Committee full hearing on electronic health records and was part of a team that defended a generic pharmaceutical manufacturer in an Actavis reverse payment enquiry at the Federal Trade Commission.

In addition, Charlie has authored and reviewed numerous freedom-to-operate, invalidity, and non-infringement opinions, including opinions supporting Paragraph IV certification for ANDA filers under the Hatch-Waxman Act. He has advised companies on the use of post-grant U.S. Patent and Trademark Office proceedings to achieve IP goals.

Prior to becoming a patent professional, Charlie spent a decade as a medicinal chemist and early-phase project co-chair at Bristol-Myers Squibb Company, where he won a Presidential Award, among other accolades. He holds Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professionals Society.